PLSE vs INMD

InMode Ltd.

(INMD) offers the better valuation at 9. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Pulse Biosciences, Inc. (PLSE) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pulse Biosciences, Inc.

(PLSE) delivered a total return of +17. 0%, compared to -61. 5% for InMode Ltd. (INMD). Over 10 years, the gap is even starker: PLSE returned +357. 6% versus INMD's +105. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), InMode Ltd.

(INMD) is the lower-risk stock at 1. 00β versus Pulse Biosciences, Inc. 's 1. 91β — meaning PLSE is approximately 91% more volatile than INMD relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 9% for Pulse Biosciences, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Pulse Biosciences, Inc.

grew EPS -17. 4% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, INMD leads at -6. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -207. 9% for Pulse Biosciences, Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -219. 8% for PLSE. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PLSE: 57.

2% to $30. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, InMode Ltd.

(INMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), +105. 6% 10Y return). Pulse Biosciences, Inc. (PLSE) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INMD: +105. 6%, PLSE: +357. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PLSE is a small-cap quality compounder stock; INMD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.